Key facts
- DName-iT’s last known valuation is $6.2M (Mar 2025).
- It has raised $1.1M; the latest was Later Stage VC ($450K) in Mar 2025.
- Notable investors include MNL Nominees, BNP Paribas, EMV Capital, EMV Capital (Acquired), KBC Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for DName-iT
- ·The full record, as it builds
Funding rounds
No funding rounds for DName-iT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DName-iT
Developer of a genetic testing technology designed to avoid sample authentication errors. The company's core product molecules allow absolute control and automation of a broad range of tests in different fields in genetic labs, where one can confirm the patient's identity, avoiding independent patient validation steps such as additional SNP fingerprint testing, making the entire NGS workflow less time-consuming and more cost-efficient, enabling lab owners to test samples more effectively and efficiently.
- Sector
- Healthcare
- HQ
- Belfast, United Kingdom
- Founded
- 2014
- Employees
- 2
- Website
- dnameit.com/
- Ownership
- Privately Held (backing)
DName-iT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DName-iT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DName-iT in its N-PORT filings yet. We sweep new filings monthly.